Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick F Smith

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
British Journal of Clinical Pharmacology|June 22, 2017
A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteersPatrick F Smith, Janakan Krishnarajah, Philip A Nunn, et al.
Diagnostic Microbiology and Infectious Disease|August 26, 2006
Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic modelPatrick F Smith, Brian Tsuji, Brent M Booker, et al.
Biochemical Pharmacology|January 24, 2007
Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependentRami G Azrak, Shousong Cao, Lakshmi Pendyala, et al.
Cancer Chemotherapy and Pharmacology|July 13, 2005
Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemiaHans Minderman, Kieran L O'Loughlin, Patrick F Smith, et al.
Cancer Chemotherapy and Pharmacology|November 9, 2007
A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumorsMarwan G Fakih, Lakshmi Pendyala, William Brady, et al.
Clinical and Translational Science|March 18, 2022
A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjectsSibel Ucpinar, Borje Darpo, Ann Neale, et al.
Antiviral Research|March 11, 2020
Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge studySusan E Sloan, Kristy J Szretter, Bharathi Sundaresh, et al.
Molecular Cancer Therapeutics|May 18, 2005
Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumorsRami G Azrak, Jinsheng Yu, Lakshmi Pendyala, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2006
Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavirElinore F McCance-Katz, David E Moody, Patrick F Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumorsMarwan G Fakih, Lakshmi Pendyala, Patrick F Smith, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
British Journal of Clinical Pharmacology|June 22, 2017
A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteersPatrick F Smith, Janakan Krishnarajah, Philip A Nunn, et al.
Diagnostic Microbiology and Infectious Disease|August 26, 2006
Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic modelPatrick F Smith, Brian Tsuji, Brent M Booker, et al.
Biochemical Pharmacology|January 24, 2007
Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependentRami G Azrak, Shousong Cao, Lakshmi Pendyala, et al.
Cancer Chemotherapy and Pharmacology|July 13, 2005
Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemiaHans Minderman, Kieran L O'Loughlin, Patrick F Smith, et al.
Cancer Chemotherapy and Pharmacology|November 9, 2007
A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumorsMarwan G Fakih, Lakshmi Pendyala, William Brady, et al.
Clinical and Translational Science|March 18, 2022
A thorough QTc study to evaluate the effects of oral rilzabrutinib administered alone and with ritonavir in healthy subjectsSibel Ucpinar, Borje Darpo, Ann Neale, et al.
Antiviral Research|March 11, 2020
Clinical and virological responses to a broad-spectrum human monoclonal antibody in an influenza virus challenge studySusan E Sloan, Kristy J Szretter, Bharathi Sundaresh, et al.
Molecular Cancer Therapeutics|May 18, 2005
Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumorsRami G Azrak, Jinsheng Yu, Lakshmi Pendyala, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 17, 2006
Interactions between buprenorphine and antiretrovirals. II. The protease inhibitors nelfinavir, lopinavir/ritonavir, and ritonavirElinore F McCance-Katz, David E Moody, Patrick F Smith, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 21, 2006
A phase I and pharmacokinetic study of fixed-dose selenomethionine and irinotecan in solid tumorsMarwan G Fakih, Lakshmi Pendyala, Patrick F Smith, et al.
Pageof 7